Disabling pansclerotic morphea of childhood

References

• Black CM. Scleroderma and fasciitis in children. Curr. Opin. Rheumatol.7, 442–448 (1995).
   Google Scholar
• Zulian F, Athreya BH, Laxer R et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology45, 614–620 (2006).
   PubMed Web of Science ®Google Scholar
• Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin. Dermatol.24, 374–392 (2006).
   Google Scholar
• Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch. Dermatol.116, 169–173 (1980).
   Google Scholar
• Rowell NR. Acral pansclerotic morphea with intractable pain. In: Clinical Dermatology – The CMD Case Collection. Wilkinson DS, Mascaró JM, Orfanos CE (Eds). Schattauer, Stuttgart, Germany, 178–180 (1987).
   Google Scholar
• Wollina U, Looks A, Uhlemann C, Wollina K. Pansclerotic morphoea of childhood – follow-up over 6 years. Pediatr. Dermatol.16, 245–247 (1999).
   Google Scholar
• Zulian F, Vallongo C, Woo P et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum.52, 2873–2881 (2005).
   PubMed Web of Science ®Google Scholar
• Singh DS, Kumar L, Radotra BD. Disabling morphea of childhood and hypogammaglobulinemia: a curious association. Rheumatol. Int.21, 158–160 (2002).
   Google Scholar
• Rosenberg AM, Uziel Y, Krafchik BR et al. Antinuclear antibodies in children with localized scleroderma. J. Rheumatol.22, 2337–2343 (1995).
   Google Scholar
• Bodemer C, Belon M, Hamel-Teillac D et al. Scleroderma in children: a retrospective study of 70 cases. Ann. Dermatol. Venereol.126, 691–694 (1999).
   Google Scholar
• Tay YK. Topical calcipotriol ointment in the treatment of morphea. J. Dermatol. Treat.14, 219–221 (2003).
   PubMedGoogle Scholar
• Manusco G, Berdonini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br. J. Dermatol.152, 180–182 (2005).
   Google Scholar
• Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br. J. Dermatol.153, 815–820 (2005).
   PubMed Web of Science ®Google Scholar
• Blaszczyk M, Krysicka Janninger C, Jablonska S. Childhood scleroderma and its peculiarities. Cutis58, 141–152 (1995).
   Google Scholar
• Möhrenschläger M, Jung C, Ring J, Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique. Pediatr. Dermatol.16, 314–316 (1999).
   Google Scholar
• Nguyen XH, Hansen R, Valencia F. Severe ankle deformity secondary to pansclerotic morphea in a 9-year-old girl: correction involving arthrodesis and free flap coverage. Pediatr. Dermatol.19, 560–563 (2002).
   Google Scholar
• Fitch PG, Rettig P, Burnham JM et al. Treatment of pediatric localized scleroderma with methotrexate. J. Rheumatol.33, 609–614 (2006).
   PubMed Web of Science ®Google Scholar
• Kawashima H, Watanabe C, Kashiwagi Y et al. Therapy of childhood generalized morphea: case reports and reviews of the literature of Japanese cases. Pediatr. Int.48, 342–348 (2006).
   Google Scholar
• Kreuter A, Gambichler T, Breuckmann F et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch. Dermatol.141, 847–852 (2005).
   PubMedGoogle Scholar
• Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J. Pediatr.136, 91–95 (2000).
   PubMed Web of Science ®Google Scholar
• Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br. J. Dermatol.155, 1013–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Cantwell AR Jr, Jones JE, Kelso DW. Pleomorphic, variably acid-fast bacteria in an adult patient with disabling pansclerotic morphea. Arch. Dermatol.120, 656–661 (1984).
   Google Scholar
• El-Mofty M, Mostafa W, El-Darouty M et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. A clinico-pathologic study. Photodermatol. Photoimmunol. Photomed.20, 148–156 (2004).
   PubMed Web of Science ®Google Scholar
• El-Mofty M, Mostafa W, Esmat S et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol. Photoimmunol. Photomed.20, 93–100 (2004).
   PubMed Web of Science ®Google Scholar
• Stege H, Berneburg M, Humke S et al. High-dose UVA1 radiation therapy for localized scleroderma. J. Am. Acad. Dermatol.36, 938–944 (1997).
   PubMed Web of Science ®Google Scholar
• Kerscher M, Volkenandt M, Gruss C et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J. Am. Acad. Dermatol.38, 21–26 (1998).
   Google Scholar
• Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J. Am. Acad. Dermatol.54, 440–447 (2006).
   PubMed Web of Science ®Google Scholar
• Kerscher M, Gambichler T, Avermaete A et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr. Dermatol.18, 241–245 (2001).
   Google Scholar
• Kreuter A, Huyn J, Skrygan M et al. Ultraviolet A1-induced downregulation of human β-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br. J. Dermatol.155, 600–607 (2006).
   PubMed Web of Science ®Google Scholar
• Kreuter A, Hyun J, Skrygan M et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch. Dermatol. Res.298, 265–272 (2006).
   Google Scholar
• Sawada H, Isogazi Z, Morita A. Altered decorin expression of systemic sclerosis by UVA1 (340–400 nm) phototherapy: immunohistochemical analysis of 3 cases. BMC Dermatol.3, 2 (2003).
   Google Scholar
• Kerscher M, Meurer M, Sander C et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch. Dermatol.132, 1280–1282 (1996).
   PubMedGoogle Scholar
• Knobler RM, French LE, Kim Y et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J. Am. Acad. Dermatol.54, 793–799 (2006).
   PubMed Web of Science ®Google Scholar
• Scharfetter-Kochanek K, Goldermann R, Lehmann P, Hölzle E, Goerz G. PUVA therapy in disabling morphoea of children. Br. J. Dermatol.132, 830–831 (1995).
   Google Scholar
• Gruss C, Stücker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br. J. Dermatol.136, 293–294 (1997).
   Google Scholar
• Todd DJ, Askari A, Ektaisch E. PUVA therapy for disabling pansclerotic morphoea of children. Br. J. Dermatol.138, 201–202 (1998).
   Google Scholar
• Yildirim M, Baysal V, Aridogan BC, Kesici D, Erturan I. Pansclerotic morphea treated with UVA: a case report. J. Dermatol.30, 625–627 (2003).
   PubMed Web of Science ®Google Scholar
• Stücker M, Schreiber D, Gruss C et al. Severe course of a mutilating pansclerotic circumscribed scleroderma in childhood. Clinical aspects and therapy. Hautarzt50, 131–135 (1999).
   Google Scholar
• Pasic A, Ceovic R, Lipozencic J et al. Phototherapy in pediatric patients. Pediatr. Dermatol.20, 71–77 (2003).
   PubMed Web of Science ®Google Scholar
• Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur. J. Dermatol.16, 340–348 (2006).
   PubMed Web of Science ®Google Scholar
• Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J. Invest. Dermatol.120, 325–331 (2003).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Komatsu S, Ibe M et al. ATX-S10(Na)-PDT shows more potent effect on collagen metabolism of human normal and scleroderma dermal fibroblasts than ALA-PDT. Arch. Dermatol. Res.298, 257–263 (2006).
   Google Scholar
• von Schmiedeberg S, Artik S, Assmann T, Megahed M, Ruzicka T. Treatment of therapy-resistant acral ulcers with iloprost. Hautarzt55, 1150–1153 (2004).
   Google Scholar
• Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr. Pharm. Des.12, 3439–3457 (2006).
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr. Pharm. Des.12, 3485–3494 (2006).
   PubMed Web of Science ®Google Scholar
• Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation112, 2980–2985 (2005).
   PubMed Web of Science ®Google Scholar
• Yung A, Reay N, Goodfield MD. Improvement in digital flexibility and dexterity following ingestion of sildenafil citrate (Viagra) in limited systemic sclerosis. Arch. Dermatol.141, 831–833 (2005).
   PubMed Web of Science ®Google Scholar
• Colgazier CL, Sutej PG, O’Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. J. Rheumatol.32, 2440–2442 (2005).
   Google Scholar
• Oldfield C, Lyseng-Williamson KA. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am. J. Cardiovasc. Drugs6, 189–208 (2006).
   Google Scholar
• Korn JH, Mayes M, Matucci Cerini M et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum.50, 3985–3993 (2004).
   PubMed Web of Science ®Google Scholar
• Rösener I, Rübben A. Treatment of a leg ulcer with bosentan in a female patient with progressive systemic scleroderma. Hautarzt58, 392–393 (2007).
   Google Scholar
• Roldan R, Morote G, Castro Mdel C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling morphea in children. J. Rheumatol.33, 2538–2540 (2006).
   Google Scholar
• Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphoea of childhood. Pediatr. Dermatol.19, 151–154 (2002).
   Google Scholar
• Doede T, Wollina U, Hindermann W, Schier F, Bondartschuk M. Pansclerotic morphea in childhood: a case report. Pediatr. Surg. Int.19, 406–408 (2003).
   Google Scholar
• Wollina U. Increased risk of cancer in scleroderma: no risk in patients with morphoea? Ann. Rheum. Dis.62, 611–612 (2003).
   Google Scholar
• Nagai Y, Hattori T, Ishikawa O. Unilateral generalized morphea in childhood. J. Dermatol.29, 435–438 (2002).
   Google Scholar
• Wollina U, Buslau M, Heinig B et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int. J. Lower Extr. Wounds (2007) [in press].
   Google Scholar